Careers

Contact

logo
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • HSCA Connect
  • Events
    • 2025 HSCA National Pharmacy Forum
    • Past Events
  • Issues
  • Resources
    • Congressional Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • COVID-19 Recommendations
    • COVID-19 Response Efforts
  • News
  • About
    • Mission
    • What Is A GPO ?
    • Policy Positions
    • HSCA Committees
    • Member Organizations
    • FAQ
    • Leadership
    • HSCA Staff
    • Contact
  • HSCA Connect
  • Events
    • 2025 HSCA National Pharmacy Forum
    • Past Events
  • Issues
  • Resources
    • Congressional Resources
    • Studies
    • Hospital Testimonials
    • Supplier Endorsements
    • COVID-19 Recommendations
    • COVID-19 Response Efforts
  • News

HSCA Applauds House Committee on Energy and Commerce for Commitment to Supporting Quality and Protecting Patients from Counterfeit Medical Products

March 11, 2020 by Brigid Hasson 2019 Press Releases 0 comments

Washington, DC (March 11, 2020) – Healthcare Supply Chain Association (HSCA) President and CEO Khatereh Calleja today released the following statement in conjunction with the House Committee on Energy and Commerce’s open mark-up session on the Safeguarding Therapeutics Act and twelve other bills:

“HSCA and its member group purchasing organizations (GPOs) applaud Representatives Engel, Guthrie, and all members of the House Committee on Energy and Commerce for helping to protect the healthcare supply chain by working to advance the Safeguarding Therapeutics Act. As the United States continues to address the spread of the coronavirus, strengthening the healthcare supply chain is more important than ever before. The Safeguarding Therapeutics Act enhances the U.S. Food and Drug Administration’s (FDA) authority to destroy counterfeit drugs and medical devices at American ports of entry, preventing such products from entering the supply chain and helping to ensure a safe and reliable supply of products.

Click here to read the full statement.

Prev
Next

Related Posts

Comments of the Healthcare Supply Chain Association to FDA on Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions
January 11, 2019

On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...

Learn more
HSCA Announces 2019 Board of Directors and Names GNYHA Ventures President Lee Perlman Board Chair
January 24, 2019

Washington, DC (January, 2019) – The Healthcare Supply Chain Association (HSCA)...

Learn more
HSCA Names Leading National Healthcare Expert Khatereh Calleja as President & CEO
April 2, 2019

Washington, DC (April 2, 2019) – The Healthcare Supply Chain Association (HSCA)...

Learn more
HSCA E&C Letter on Improving Competition in the Generic Marketplace
April 1, 2019

Dear Chairman Pallone and Ranking Member Walden, I am writing to you on behalf...

Learn more

Our Office

Healthcare Supply Chain Association
750 9th Street NW, Suite 650
Washington, DC 20001

Phone: 202.629.5833
Fax: 202.466.9666
Email: info@supplychainassociation.org

LATEST NEWS

  • HSCA Response to the U.S. Department of Commerce’s Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
    May 8, 2025
  • HSCA Response to the U.S. Trade Representative’s Request for Comments on Unfair and Non-Reciprocal Foreign Trade Practices
    March 12, 2025